Charles River Labs Licenses CRISPR/Cas9 IP from ERS Genomics

Charles River Laboratories has expanded its available CRISPR/Cas9 offerings to include both technologies at the center of the bitter legal battle over who first invented the genome-editing application.Charles River has licensed from ERS Genomics nonexclusive access to ERS’s CRISPR/Cas9 patents, which are based on the technology that, in turn, ERS has licensed from holders of a European patent granted in March —namely the Regents of the University of California (UC), the University of